Biogen Pilot on Using Vocal Biomarkers to Identify Potential Trial Participants: From the DPHARM 2024 Archives
Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to identify potential patients and reduce the burden of pre-screening.

In this podcast from the DPHARM 2024 archives, Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition, and to reduce the burden of pre-screening.
For more information, go to DPHARMconference.com.
Related Podcasts
View All
Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach, from DPHARM 2024 Archives

Joint Site and Sponsor Perspectives on Innovative Solutions Addressing Sites Challenges

Directors' Talk DPHARM 2025 - Pharma from the Trenches; Part II
